Brief: Eledon Reports Updated Data From Ongoing Phase 1B Trial Evaluating Tegoprubart
02/11/2023 13:07
Nov 2 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O :
* ELEDON REPORTS UPDATED DATA FROM ONGOING PHASE 1B TRIAL
EVALUATING TEGOPRUBART FOR PREVENTION OF REJECTION IN KIDNEY
TRANSPLANTATION
* ELEDON PHARMACEUTICALS - DATA DEMONSTRATES TEGOPRUBART
SUCCESSFULLY PREVENTED KIDNEY TRANSPLANT REJECTION AND WAS
GENERALLY SAFE AND WELL-TOLERATED
* ELEDON PHARMACEUTICALS INC - NO CASES OF HYPERGLYCEMIA,
NEW
ONSET DIABETES, TREMOR, OR CYTOMEGALOVIRUS INFECTION COMMONLY
SEEN WITH TACROLIMUS
* ELEDON PHARMACEUTICALS INC - ONE PARTICIPANT EXPERIENCED A
MILD
T CELL MEDIATED REJECTION (BANFF SCORE 1A) ON DAY 99
* ELEDON PHARMACEUTICALS INC - PATIENT WAS TREATED FOR
REJECTION
AND REMAINS IN STUDY
* ELEDON PHARMACEUTICALS INC - THERE WERE NO CASES OF GRAFT
LOSS
OR DEATH
Source text for Eikon: ID:nGNX4JSBxl
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial